Universal Beteiligungs und Servicegesellschaft mbH Acquires 33,065 Shares of Beam Therapeutics Inc. $BEAM

Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) by 88.8% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 70,280 shares of the company’s stock after buying an additional 33,065 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.07% of Beam Therapeutics worth $1,706,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the business. Allworth Financial LP boosted its holdings in shares of Beam Therapeutics by 7,080.0% during the 2nd quarter. Allworth Financial LP now owns 2,513 shares of the company’s stock valued at $43,000 after acquiring an additional 2,478 shares during the last quarter. Daiwa Securities Group Inc. boosted its holdings in Beam Therapeutics by 1,248.8% in the second quarter. Daiwa Securities Group Inc. now owns 3,817 shares of the company’s stock worth $65,000 after purchasing an additional 3,534 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Beam Therapeutics by 43.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,884 shares of the company’s stock worth $66,000 after purchasing an additional 1,175 shares during the last quarter. Bayforest Capital Ltd bought a new stake in Beam Therapeutics in the 3rd quarter worth approximately $114,000. Finally, Wealth Effects LLC purchased a new stake in Beam Therapeutics during the 3rd quarter valued at $223,000. Hedge funds and other institutional investors own 99.68% of the company’s stock.

Wall Street Analyst Weigh In

BEAM has been the topic of a number of research reports. Wall Street Zen upgraded Beam Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Sanford C. Bernstein raised their target price on Beam Therapeutics from $37.00 to $41.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Beam Therapeutics in a research note on Wednesday, January 21st. Benchmark reaffirmed a “speculative buy” rating on shares of Beam Therapeutics in a research report on Monday, November 17th. Finally, Tudor Pickering set a $41.00 price objective on shares of Beam Therapeutics in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.80.

Beam Therapeutics Trading Down 5.7%

Shares of NASDAQ:BEAM opened at $27.62 on Friday. The stock has a 50 day moving average of $28.24 and a 200 day moving average of $24.03. The company has a market cap of $2.80 billion, a PE ratio of -6.23 and a beta of 2.07. Beam Therapeutics Inc. has a 12-month low of $13.52 and a 12-month high of $36.44.

Beam Therapeutics (NASDAQ:BEAM) last released its earnings results on Tuesday, November 4th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.12). The firm had revenue of $9.70 million for the quarter, compared to the consensus estimate of $12.83 million. Beam Therapeutics had a negative return on equity of 42.86% and a negative net margin of 744.41%.Beam Therapeutics’s revenue was down 32.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.17) EPS. Equities research analysts predict that Beam Therapeutics Inc. will post -4.57 earnings per share for the current fiscal year.

Insider Activity at Beam Therapeutics

In related news, insider Christine Bellon sold 1,371 shares of Beam Therapeutics stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $34.00, for a total transaction of $46,614.00. Following the transaction, the insider owned 95,667 shares in the company, valued at approximately $3,252,678. The trade was a 1.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 3.50% of the stock is owned by insiders.

Beam Therapeutics Company Profile

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.